Business
Mesoblast treatment gets US panel’s key tick of approval – Sydney Morning Herald
The drug that Mesoblast has been trialling on some COVID-19 patients has just got the nod from a US regulator panel for treating children with severe responses to bone marrow transplants.
Stem cell treatment producer Mesoblast has recorded a significant win after the US FDA’s Oncologic Drugs Advisory Committee voted in favour of its flagship product for treating children with severe responses to bone marrow transplants.
The planned meeting of the US regulator had sent Mesoblast shares on a rollercoaster this week. The multi-billion company’s share price dropped more than 30 per cent in a single session on Tuesday after briefing papers released ahead of the meeting revealed the w…
-
Noosa News19 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General11 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News18 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General13 hours agoPerth man charged after investigation into organised crime and tobacco store attacks